153 related articles for article (PubMed ID: 32995481)
1. High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma.
Delaunay T; Nader J; Grard M; Farine I; Hedwig V; Foloppe J; Blondy T; Violland M; Pouliquen D; Grégoire M; Boisgerault N; Erbs P; Fonteneau JF
Mol Ther Oncolytics; 2020 Sep; 18():573-578. PubMed ID: 32995481
[TBL] [Abstract][Full Text] [Related]
2. Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
Kelly KJ; Woo Y; Brader P; Yu Z; Riedl C; Lin SF; Chen N; Yu YA; Rusch VW; Szalay AA; Fong Y
Hum Gene Ther; 2008 Aug; 19(8):774-82. PubMed ID: 18754710
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.
Acuna SA; Ottolino-Perry K; Çako B; Tang N; Angarita FA; McCart JA
Ann Surg Oncol; 2014 Jul; 21(7):2259-66. PubMed ID: 24719018
[TBL] [Abstract][Full Text] [Related]
4. The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.
Foloppe J; Kempf J; Futin N; Kintz J; Cordier P; Pichon C; Findeli A; Vorburger F; Quemeneur E; Erbs P
Mol Ther Oncolytics; 2019 Sep; 14():1-14. PubMed ID: 31011628
[TBL] [Abstract][Full Text] [Related]
5. Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.
Adusumilli PS; Stiles BM; Chan MK; Mullerad M; Eisenberg DP; Ben-Porat L; Huq R; Rusch VW; Fong Y
J Gene Med; 2006 May; 8(5):603-15. PubMed ID: 16475242
[TBL] [Abstract][Full Text] [Related]
6. Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
Delaunay T; Achard C; Boisgerault N; Grard M; Petithomme T; Chatelain C; Dutoit S; Blanquart C; Royer PJ; Minvielle S; Quetel L; Meiller C; Jean D; Fradin D; Bennouna J; Magnan A; Cellerin L; Tangy F; Grégoire M; Fonteneau JF
J Thorac Oncol; 2020 May; 15(5):827-842. PubMed ID: 31945495
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
8. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
9. Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase.
Islam SMBU; Lee B; Jiang F; Kim EK; Ahn SC; Hwang TH
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963415
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
Fend L; Remy-Ziller C; Foloppe J; Kempf J; Cochin S; Barraud L; Accart N; Erbs P; Fournel S; Préville X
Oncoimmunology; 2016 Feb; 5(2):e1080414. PubMed ID: 27057460
[TBL] [Abstract][Full Text] [Related]
11. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.
Silberhumer GR; Brader P; Wong J; Serganova IS; Gönen M; Gonzalez SJ; Blasberg R; Zamarin D; Fong Y
Mol Cancer Ther; 2010 Oct; 9(10):2761-9. PubMed ID: 20858727
[TBL] [Abstract][Full Text] [Related]
13. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma.
Yurttas C; Beil J; Berchtold S; Smirnow I; Kloker LD; Sipos B; Löffler MW; Königsrainer A; Mihaljevic AL; Lauer UM; Thiel K
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254857
[TBL] [Abstract][Full Text] [Related]
15. Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators.
Gallardo F; Schmitt D; Brandely R; Brua C; Silvestre N; Findeli A; Foloppe J; Top S; Kappler-Gratias S; Quentin-Froignant C; Morin R; Lagarde JM; Bystricky K; Bertagnoli S; Erbs P
Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33256205
[TBL] [Abstract][Full Text] [Related]
16. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
Watanabe Y; Kojima T; Kagawa S; Uno F; Hashimoto Y; Kyo S; Mizuguchi H; Tanaka N; Kawamura H; Ichimaru D; Urata Y; Fujiwara T
Oncogene; 2010 Feb; 29(8):1145-54. PubMed ID: 19935710
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.
Adusumilli PS; Chan MK; Chun YS; Hezel M; Chou TC; Rusch VW; Fong Y
Cancer Biol Ther; 2006 Jan; 5(1):48-53. PubMed ID: 16294031
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic properties of non-vaccinia poxviruses.
Ricordel M; Foloppe J; Pichon C; Findeli A; Tosch C; Cordier P; Cochin S; Quémeneur E; Camus-Bouclainville C; Bertagnoli S; Erbs P
Oncotarget; 2018 Nov; 9(89):35891-35906. PubMed ID: 30542506
[TBL] [Abstract][Full Text] [Related]
19. Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development.
Ho TY; Mealiea D; Okamoto L; Stojdl DF; McCart JA
Mol Ther Oncolytics; 2021 Sep; 22():85-97. PubMed ID: 34514091
[TBL] [Abstract][Full Text] [Related]
20. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
